ADORA2A
-
Official Full Name
Adora2a adenosine A2a receptor
-
Synonyms
ADORA2A; adenosine A2a receptor; adenosine receptor A2a; A2a, Rs; A2aR; A2AAR; AA2AR; MGC118414;
- Recombinant Proteins
- Cell & Tissue Lysates
- Protein Pre-coupled Magnetic Beads
- Canis lupus familiaris (Dog) (Canis familiaris)
- Cavia porcellus (Guinea pig)
- Equus caballus (Horse)
- Guinea pig
- Human
- Mouse
- Mus musculus (Mouse)
- Rat
- Rattus norvegicus (Rat)
- E.coli
- E.coli expression system
- E.Coli or Yeast
- HEK293
- In Vitro Cell Free System
- Insect Cell
- Mammalian Cell
- Wheat Germ
- GST
- His
- Fc
- Avi
- Flag
- TrxA
- Non
- Involved Pathway
- Protein Function
- Interacting Protein
- Other Resource
ADORA2A involved in several pathways and played different roles in them. We selected most pathways ADORA2A participated on our site, such as Activation of TRKA receptors, Adenosine P1 receptors, Alcoholism, which may be useful for your reference. Also, other proteins which involved in the same pathway with ADORA2A were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
Activation of TRKA receptors | ADCYAP1R1;NTF7;ADCYAP1;ADORA2A |
Adenosine P1 receptors | ADORA2A;ADORA2B;ADORA3;ADORA1 |
Alcoholism | CALM4;CREB3L3;HIST1H4C;GM14478;SLC18A1;HIST2H2BE;DRD1;CALM2;HIST1H4G |
Calcium signaling pathway | ATP2B4;ADRB1;EDNRA;DRD7;TNNC1A;ITPKA;CCKBR;CALM2B;CALM2A |
Class A/1 (Rhodopsin-like receptors) | EDN3;PROKR1;NPB;AGTR2;NPS;PYYA;GPR4;ADRB3;TAC3 |
G alpha (s) signalling events | VIP2;RXFP2B;GHRH;CRHB;ADCYAP1R1;CRHR2;TAAR1;RLN3;RLN3A |
GPCR downstream signaling | HCRT;AGTR2;HEBP1;OPN1LW1;ANXA1A;INSL5;CNR1;NPB;EDNRA |
GPCR ligand binding | GRP;CASR;GPR77;FPR-RS6;RHOL;PTHRP2;INSL5;ADORA1;FFAR3 |
ADORA2A has several biochemical functions, for example, G-protein coupled adenosine receptor activity, alpha-actinin binding, enzyme binding. Some of the functions are cooperated with other proteins, some of the functions could acted by ADORA2A itself. We selected most functions ADORA2A had, and list some proteins which have the same functions with ADORA2A. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
G-protein coupled adenosine receptor activity | ADORA3;ADORA2AA;P2RY12;ADORA2AB;ADORA2B;ADORA1;ADORA2A |
alpha-actinin binding | KCNN2;RARA;MAGI1;KCNA5;LRRC10;ALMS1;PKD2L1;ADORA2A;DAG1 |
enzyme binding | TBP;KDM1A;YWHAE;HSPA6;APBA3;NOTCH1;NKX2-1;SLC18A1;KAT8 |
identical protein binding | SERPINA1A;CPT1A;TRIM23;CLDND;RUNX1T1;TRADD;BAG2;S100A2;BLOC1S6 |
protein binding | C7orf49;IL23;CHUK;SURF1;VMP1;SUDS3;MAL2;TECPR1;CXXC11 |
protein heterodimerization activity | Defa-rs7;HIST1H2BA;TCF4;ADIPOR1;CUL3;H2AFY;TPD52L1;OSTA;HMG20A |
type 5 metabotropic glutamate receptor binding | HOMER1;ADORA2A;DNM3 |
ADORA2A has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with ADORA2A here. Most of them are supplied by our site. Hope this information will be useful for your research of ADORA2A.
CYTH2; NECAB2; USP4
- Reviews
- Q&As
Customer Reviews (5)
Write a reviewThe manufacturer has gone above and beyond in providing detailed protocols and troubleshooting guides, which have been invaluable in optimizing my experiments.
the manufacturer's technical support is exemplary and can effectively address any concerns or issues that may arise during the course of my research.
Based on my analysis, the ADORA2A protein is of exceptional quality and will cater to the experimental requirements.
I appreciate the level of support being offered and the willingness of the manufacturer to promptly address any queries or concerns.
I am confident that I made the right choice in selecting this product and manufacturer, and I am excited to continue using it for my research.
Q&As (13)
Ask a questionADORA2A is involved in the regulation of the cardiovascular system by mediating the effects of adenosine, which is released from damaged cells in response to tissue injury or hypoxia. ADORA2A activation can lead to vasodilation, which increases blood flow and oxygen delivery to the affected tissues. Additionally, ADORA2A activation can reduce heart rate and blood pressure, which can be beneficial in certain cardiovascular conditions.
ADORA2A agonists and antagonists have been investigated as potential therapeutics for a variety of conditions. For example, ADORA2A agonists have been tested for their potential to reduce inflammation in diseases like asthma and chronic obstructive pulmonary disease (COPD), as well as for their potential to improve cognitive function in Alzheimer's disease and Parkinson's disease. ADORA2A antagonists have been investigated as potential treatments for depression, anxiety, and addiction, as they may increase the activity of dopamine neurons in the brain.
ADORA2A agonists and antagonists have a range of potential therapeutic applications. ADORA2A agonists have been investigated as potential treatments for various conditions including inflammation, neurodegenerative disorders, and cardiac ischemia/reperfusion injury. ADORA2A antagonists have also shown potential as therapeutic agents for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and Parkinson's disease. In asthma and COPD, ADORA2A antagonists can block the bronchospasm-inducing effects of adenosine, improving lung function. In Parkinson's disease, ADORA2A antagonists have been shown to improve motor function and reduce levodopa-induced dyskinesia. Additionally, ADORA2A antagonists have been investigated as potential treatments for cognitive impairment and depression.
ADORA2A has been shown to exert immunosuppressive effects on the immune system. Adenosine, the ligand for ADORA2A, is produced by various cells in response to tissue damage or inflammation, and acts to suppress immune cell activation, cytokine production and T cell proliferation. This helps to limit the inflammatory response and prevent autoimmune reactions. In addition, ADORA2A expression has been found on a wide range of immune cells, including T cells, B cells, dendritic cells and macrophages, indicating that ADORA2A signaling is involved in the regulation of various aspects of immune function.
Yes, there are several genetic mutations associated with ADORA2A that have been linked to various diseases. For example, a genetic variant in the ADORA2A gene has been found to be associated with an increased risk of Parkinson's disease. Another variant has been linked to an increased risk of developing schizophrenia. These findings suggest that genetic variations in ADORA2A may impact the risk of developing certain neurological and psychiatric disorders.
ADORA2A has anti-inflammatory effects and can modulate the immune response to inflammation. Adenosine, the ligand for ADORA2A, is produced during tissue damage and inflammation and acts to suppress immune cell activation, cytokine production and T cell proliferation. This helps to limit the inflammatory response and prevent autoimmune reactions. Additionally, ADORA2A expression has been found on a wide range of immune cells, including T cells, B cells, dendritic cells and macrophages, indicating that ADORA2A signaling is involved in the regulation of various aspects of immune function. ADORA2A agonists have been investigated as potential treatments for inflammatory conditions such as rheumatoid arthritis and Crohn's disease.
Yes, some food and supplements have been shown to affect ADORA2A activity. For example, caffeine and theophylline (found in tea and chocolate) are known ADORA2A antagonists and can block the effects of adenosine in the brain. On the other hand, green tea and chocolate, which contain epigallocatechin gallate (EGCG) and epicatechin, respectively, have been shown to activate ADORA2A and improve cognitive function. Resveratrol, found in red wine and grapes, also activates ADORA2A and has been shown to improve cardiovascular health.
ADORA2A can be targeted in therapy using various methods, including small molecule agonists or antagonists, monoclonal antibodies, and gene therapy. Small molecule agonists or antagonists can be administered orally or intravenously and can easily penetrate the blood-brain barrier to target ADORA2A in the brain. Monoclonal antibodies can be used to selectively target ADORA2A-expressing cells, while gene therapy can be used to modulate ADORA2A expression in specific tissues.
Yes, ADORA2A has been implicated in the development of cancer and its progression. ADORA2A activation can promote tumor growth and metastasis, while ADORA2A antagonists have been shown to inhibit tumor growth and improve immune response against cancer cells. Therefore, ADORA2A has been investigated as a potential target for cancer therapy, and several ADORA2A antagonists are currently in preclinical and clinical development for various cancers.
ADORA2A has been shown to have several cardiovascular effects, including vasodilation, inhibition of smooth muscle cell proliferation, and protection against ischemia/reperfusion injury. ADORA2A expression has been detected in the heart, blood vessels, and endothelial cells, indicating that it is involved in the regulation of cardiovascular function. ADORA2A activation leads to the release of nitric oxide and cGMP, both of which are potent vasodilators and contribute to improved blood flow. Additionally, ADORA2A activation has been shown to reduce myocardial infarct size and improve cardiac function following ischemia/reperfusion injury.
Yes, there are potential side effects associated with targeting ADORA2A in therapy. For example, ADORA2A agonists may cause insomnia, anxiety, and tremors, while ADORA2A antagonists may cause nausea, vomiting, and changes in blood pressure. Additionally, ADORA2A targeting may potentially increase the risk of arrhythmias in patients with underlying cardiac conditions. Therefore, careful consideration of the potential risks and benefits is necessary before using ADORA2A-targeted therapies in patients.
ADORA2A targeting has been investigated as a potential treatment for drug addiction and substance use disorders. Preclinical studies have shown that ADORA2A agonists can reduce drug addiction-related behaviors, such as drug-seeking and relapse, by modulating dopamine release in the brain reward system. Additionally, ADORA2A antagonists may reduce the rewarding effects of drugs of abuse and decrease drug-induced hyperactivity. Therefore, ADORA2A targeting may provide a new approach for managing drug addiction and substance use disorders.
Yes, there are several ongoing clinical trials investigating ADORA2A-targeted therapies for various conditions. For example, ADORA2A antagonists are being tested in clinical trials for the treatment of depression, anxiety disorders, and cocaine use disorder. An ADORA2A agonist is also being evaluated in a clinical trial for the treatment of asthma. Additionally, ADORA2A-targeted therapies are being investigated in clinical trials for cancer and cardiovascular diseases.
Ask a Question for All ADORA2A Products
Required fields are marked with *
My Review for All ADORA2A Products
Required fields are marked with *